{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:00Z","timestamp":1792008060152,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Science and Technology","award":["MOST 103-2314-B-650-002"],"award-info":[{"award-number":["MOST 103-2314-B-650-002"]}]},{"name":"Ministry of Science and Technology","award":["MOST 105-2314-B-650-001-MY2"],"award-info":[{"award-number":["MOST 105-2314-B-650-001-MY2"]}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["107VACS-003"],"award-info":[{"award-number":["107VACS-003"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["V107E-004-1"],"award-info":[{"award-number":["V107E-004-1"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tomorrow Medical Foundation","award":["106-2"],"award-info":[{"award-number":["106-2"]}]}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jhep.2018.02.032","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T15:12:59Z","timestamp":1521385979000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B"],"prefix":"10.1016","volume":"69","author":[{"given":"Yao-Chun","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu J.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Tsung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem B.","family":"El-Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Town","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2018.02.032_b0005","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.02.032_b0010","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.cgh.2015.08.014","article-title":"Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice","volume":"13","author":"Singal","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.02.032_b0015","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2011.36.2335","article-title":"Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C","volume":"29","author":"Huang","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.02.032_b0020","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate vs. adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.02.032_b0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.02.032_b0030","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir vs. lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.02.032_b0035","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0040","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2018.02.032_b0045","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1365-2036.2008.03816.x","article-title":"Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma","volume":"28","author":"Sung","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.02.032_b0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.02.032_b0055","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"Wong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0065","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.27889","article-title":"Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load","volume":"62","author":"Sinn","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0070","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first five years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0075","article-title":"Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir","author":"Hsu","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2018.02.032_b0080","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.02.032_b0085","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2018.02.032_b0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.02.032_b0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2018.02.032_b0100","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2018.02.032_b0105","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/ajg.2016.257","article-title":"Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with entecavir: results of the ENUMERATE study","volume":"111","author":"Ahn","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.02.032_b0110","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/apt.12990","article-title":"The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy","volume":"40","author":"Coffin","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2018.02.032_b0115","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/jac\/dku041","article-title":"Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B","volume":"69","author":"Hsu","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2018.02.032_b0120","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2014.08.045","article-title":"Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.02.032_b0125","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/liv.13142","article-title":"Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis","volume":"36","author":"Raffetti","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.02.032_b0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2018.02.032_b0135","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2018.02.032_b0140","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2018.02.032_b0145","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.27894","article-title":"Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects","volume":"62","author":"Wong","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0150","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2018.02.032_b0155","first-page":"609","article-title":"Structured data entry of clinical information for documentation and data collection","volume":"84","author":"Cheung","year":"2001","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.jhep.2018.02.032_b0160","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/hep.27630","article-title":"Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan","volume":"61","author":"Chiang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0165","doi-asserted-by":"crossref","first-page":"e68780","DOI":"10.1371\/journal.pone.0068780","article-title":"RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2018.02.032_b0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/liv.12868","article-title":"Red cell volume distribution width-to-platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B","volume":"36","author":"Lee","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.02.032_b0175","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0180","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/hep.24105","article-title":"Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis","volume":"53","author":"Lin","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0185","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/hep.25684","article-title":"Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study","volume":"56","author":"Hsu","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0190","series-title":"Regression modeling strategies","author":"Frank","year":"2006"},{"key":"10.1016\/j.jhep.2018.02.032_b0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.jhep.2018.02.032_b0200","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2018.02.032_b0205","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/hep.28895","article-title":"An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis","volume":"65","author":"Atiq","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0210","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ajg.2012.445","article-title":"Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community","volume":"108","author":"Wang","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.02.032_b0215","series-title":"Applied logistic regression","author":"Hosmer","year":"2004"},{"key":"10.1016\/j.jhep.2018.02.032_b0220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s005350300025","article-title":"Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis","volume":"38","author":"Hung","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.02.032_b0225","doi-asserted-by":"crossref","first-page":"e4832","DOI":"10.1097\/MD.0000000000004832","article-title":"A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation","volume":"95","author":"Nishikawa","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jhep.2018.02.032_b0230","doi-asserted-by":"crossref","first-page":"92431","DOI":"10.18632\/oncotarget.21369","article-title":"Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2018.02.032_b0235","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3350\/cmh.2016.0086","article-title":"Risk score model for the development of hepatocellular carcinoma in treatment-naive patients receiving oral antiviral treatment for chronic hepatitis B","volume":"23","author":"Sohn","year":"2017","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2018.02.032_b0240","first-page":"98A","article-title":"REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV)\u2014a risk score for the prediction of hepatocellular carcinoma (HCC) in chronic hepatitis (CHB) patients treated with oral anti-HBV therapy","author":"Nguyen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2018.02.032_b0245","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/liv.13450","article-title":"Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir","volume":"37","author":"Kim","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2018.02.032_b0250","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.cgh.2016.03.024","article-title":"Association between serum level of hepatitis B surface antigen at end of entecavir therapy and risk of relapse in e antigen-negative patients","volume":"14","author":"Hsu","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2018.02.032_b0255","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2018.02.032_b0260","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ajg.2014.145","article-title":"Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis","volume":"109","author":"Kim","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2018.02.032_b0265","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2018.12.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818301703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827818301703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T08:57:19Z","timestamp":1603961839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827818301703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0168827818301703"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2018.02.032","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2018.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}